WuXi Biologics (Cayman) Inc
HKEX:2269

Watchlist Manager
WuXi Biologics (Cayman) Inc Logo
WuXi Biologics (Cayman) Inc
HKEX:2269
Watchlist
Price: 14.4 HKD -4% Market Closed
Market Cap: 59.8B HKD
Have any thoughts about
WuXi Biologics (Cayman) Inc?
Write Note

WuXi Biologics (Cayman) Inc
Intangible Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

WuXi Biologics (Cayman) Inc
Intangible Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Intangible Assets CAGR 3Y CAGR 5Y CAGR 10Y
WuXi Biologics (Cayman) Inc
HKEX:2269
Intangible Assets
ÂĄ474.8m
CAGR 3-Years
-7%
CAGR 5-Years
8%
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Intangible Assets
ÂĄ1.8B
CAGR 3-Years
5%
CAGR 5-Years
19%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Intangible Assets
ÂĄ786m
CAGR 3-Years
6%
CAGR 5-Years
14%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Intangible Assets
ÂĄ345m
CAGR 3-Years
42%
CAGR 5-Years
60%
CAGR 10-Years
33%
M
MGI Tech Co Ltd
SSE:688114
Intangible Assets
ÂĄ659.3m
CAGR 3-Years
-3%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
W
WuXi XDC Cayman Inc
HKEX:2268
Intangible Assets
ÂĄ52.9m
CAGR 3-Years
123%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

WuXi Biologics (Cayman) Inc
Glance View

Market Cap
59.8B HKD
Industry
Life Sciences Tools & Services

WuXi Biologics (Cayman) Inc. is a leading global provider of biologics development and manufacturing solutions, operating at the intersection of healthcare innovation and advanced biotechnology. Founded in 2010, the company has rapidly transformed from a local player into a dominant force that serves pharma and biotech firms worldwide. WuXi Biologics offers a comprehensive suite of services, including cell line development, process development, clinical manufacturing, and commercial production of biologics, helping its partners bring life-saving therapies to market with speed and efficiency. With a robust pipeline of collaborations and a commitment to excellence, WuXi is strategically positioned to capitalize on the growing demand for biologics, particularly in the realms of monoclonal antibodies and gene therapies. For investors, WuXi Biologics represents a compelling opportunity in the rapidly evolving biopharmaceutical landscape. The company’s expansive global network, which includes state-of-the-art facilities in China, Europe, and the United States, allows it to meet rising demand while maintaining high-quality standards. WuXi is well-supported by a solid financial foundation, marked by impressive revenue growth and a strong balance sheet. As regulatory frameworks become more favorable and the biopharma industry continues to innovate, WuXi Biologics stands poised to drive sustainable long-term growth, making it an appealing consideration for investors looking to tap into the promising future of medical therapies.

Intrinsic Value
33.72 HKD
Undervaluation 57%
Intrinsic Value
Price

See Also

What is WuXi Biologics (Cayman) Inc's Intangible Assets?
Intangible Assets
474.8m CNY

Based on the financial report for Jun 30, 2024, WuXi Biologics (Cayman) Inc's Intangible Assets amounts to 474.8m CNY.

What is WuXi Biologics (Cayman) Inc's Intangible Assets growth rate?
Intangible Assets CAGR 5Y
8%

Over the last year, the Intangible Assets growth was -13%. The average annual Intangible Assets growth rates for WuXi Biologics (Cayman) Inc have been -7% over the past three years , 8% over the past five years .

Back to Top